Relative quantities of catalytically active CYP 2C9 in human liver microsomes: Applicaiton of the relative activity factor approach

Journal of Pharmaceutical Sciences

Volumn 87, Issue 7, 1998, Pages 845-853

  Venkatakrishnan, Karthik ^b   Von Moltke, Lisa L ^b   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; CYTOCHROME P450; OXIDOREDUCTASE; TOLBUTAMIDE;

ARTICLE; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME KINETICS; LIVER MICROSOME; MICHAELIS CONSTANT;

EID: 0031871755     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970435t     Document Type: Article

References (45)

1. Parkinson, A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathol. 1996, 24(1), 45-57.
2. Remmel, R. P.; Burchell, B. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem. Pharmacol. 1993, 46(4), 559-566.
3. Crespi, C. L. Xenobiotic metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 1995, 26, 179-235.
4. Forrester, L. M.; Henderson, C. J.; Glancey, M. J.; Back, D. J.; Park, B. K.; Ball, S. E.; Kitteringham, N. R.; McLaren, A. W.; Miles, J. S.; Skett, P.; Wolf, C. R. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 1992, 281, 359-368.
5. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270(1), 414-423.
6. Shimada, T.; Mimura, M.; Inoue, K.; Nakamura, S.; Oda, H.; Ohmori, S.; Yamazaki, H. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch. Toxicol. 1997, 71, 401-408.
7. Koyama, E.; Chiba, K.; Tani, M.; Ishizaki, T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther. 1997, 281(3), 1199-1210.
8. Kobayashi, K.; Chiba, K.; Yagi, T.; Shimada, N.; Taniguchi, T.; Horie, T.; Tani, M.; Yamamoto, T.; Ishizaki, T.; Kuroiwa, Y. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997, 280(2), 927-933.
9. Inoue, K.; Yamazaki, H.; Imiya, K.; Akasaka, S.; Guengerich, F. P.; Shimada, T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997, 7, 103-113.
10. m diazepam N-demethylases. Drug Metab. Dispos. 1997, 25(2), 133-139.
11. Flockhart, D. A. Drug interactions and the cytochrome P450 system. The role of P450 2C19. Clin. Pharmacokinet. 1995, 29(Suppl 1), 45-52.
12. Karam, W. G.; Goldstein, J. A.; Lasker, J. M.; Ghanayem, B. I. Human CYP 2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 1996, 24(10), 1081-1087.
13. Olesen, O. V.; Linnet, K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997, 25(6), 740-744.
14. Venkatakrishnan, K.; Greenblatt, D, J.; von Moltke, L. L.; Schmider, J.; Harmatz, J. S.; Shader, R. I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 1998, 38(2), 112-121.
15. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993, 47, 268-276.
16. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interaction in vivo. J. Pharmacol. Exp. Ther. 1994, 268, 1278-1283.
17. Schmider, J.; Greenblatt, D. J.; von Moltke, L. L.; Harmatz, J. S.; Duan, S. X.; Karsov, D.; Shader, R. I. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology 1996, 52, 125-34.
18. Miners, J. O.; Birkett, D. J. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol. 1996, 272, 139-145.
19. Gum, J. R.; Strobel, H. W. Purified NADPH cytochrome P-450 reductase. Interaction with hepatic microsomes and phospholipid vesicles. J. Biol. Chem. 1979, 254(10), 4177-4185.
20. Sequeira, D. J.; Strobel, H. W. In vitro metabolism of imipramine by brain microsomes: effects of inhibitors and exogenous cytochrome P450 reductase. Brain Res. 1996, 738, 24-31.
21. Yamaoka, K.; Nakagawa, T.; Uno, T. Application of Akaike's Information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6, 165-175.
22. Veronese, M. E.; Mackenzie, P. I.; Doecke, C. J.; McManus, M. E.; Miners, J. O.; Birkett, D. J. Tolbutamide and phenytoin hydroxylations by cDNA expressed human liver cytochrome P450 2C9. Biochem. Biophys. Res. Commun. 1991, 175(3), 1112-1118.
23. Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F. J.; Tsutsui, M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA expressed human P450s and human liver microsomes. Xenobiotica 1996, 26(7), 681-693.
24. Veronese, M. E.; Doecke, C. J.; Mackenzie, P. I.; McManus, M. E.; Miners, J. O.; Rees, D. L. P.; Gasser, R.; Meyer, U. A.; Birkett, D. J. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP 2C subfamily. Biochem. J. 1993, 289, 533-538.
25. Newton, D. J.; Wang, R. W.; Lu, A. Y. H. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995, 23(1), 154-158.
26. Bourrié, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277(1), 321-332.
27. Miners, J. O.; Rees, D. L. P.; Valente, L.; Veronese, M. E.; Birkett, D. J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995, 272(3), 1076-1081.
28. Leeman, T.; Transon, C.; Dayer, P. Cytochrome P450 TB (CYP 2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 1993, 52(1), 29-34.
29. Rettie, A. E.; Korzekwa, K. R.; Kunze, K. L.; Lawrence, R. F.; Eddy, A. C.; Aoyama, T.; Gelboin, H. V.; Gonzalez, F. J.; Trager, W. F. Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-450 2C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. 1992, 5, 54-59.
30. Kaminsky, L. S.; de Morais, S. M. F.; Faletto, M. B.; Dunbar, D. A.; Goldstein, J. A. Correlation of human cytochrome P450 2C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol. 1993, 43, 234-239.
31. Kaminsky, L. S.; Zhang, Z-Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73(1), 67-74.
32. Tracy, T. S.; Rosenbluth, B. W.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)-and (S)-flurbiprofen. Biochem. Pharmacol. 1995, 49(9), 1269-1275.
33. Tracy, T. S.; Marra, C.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem. Pharmacol. 1996, 52, 1305-1309.
34. Jean, P.; Lopez-Garcia, P.; Dansette, P.; Mansuy, D.; Goldstein, J. L. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem. 1996, 241, 797-804.
35. Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol. 1997, 54, 33-41.
36. Bajpai, M.; Roskos, L. K.; Shen, D. D.; Levy, R. H. Roles of cytochrome P450 2C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 1996, 24(12), 1401-1403.
37. Crespi, C. L.; Miller, V. P. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997, 7, 203-210.
38. Goldstein, J. A.; Faletto, M. B.; Romkes-Sparks, M.; Sullivan, T.; Kitareewan, S.; Raucy, J. L.; Lasker, J. M.; Ghanayem, B. I. Evidence that CYP 2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994, 33, 1743-1752.
39. Ono, S.; Hatanaka, T.; Miyazawa, S.; Tsutsu, M.; Aoyama, T.; Gonzalez, F. J.; Satoh, T. Human liver microsomal diazepam metabolism using cDNA expressed cytochrome P450s: role of CYP 2B6, 2C19 and the 3A subfamily. Xenobiotica 1996, 26(11), 1155-1166.
40. Ghahramani, S.; Ellis, S. W.; Lennard, M. S.; Ramsay, L. E.; Tucker, G. T. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 1997, 43, 137-144.
41. Purba, H. S.; Back, D. J.; Orme, L'E. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br. J. Clin. Pharmacol. 1987, 24, 230-234.
42. Back, D. J.; Tjia, J. P.; Karbwang, J.; Colbert, J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones. Br. J. Clin. Pharmacol. 1988, 26, 23-29.
43. Miners, J. O.; Smith, K. J.; Robson, R. A.; McManus, M. E.; Veronese, M. E.; Birkett, D. J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 1988, 37(6), 1137-1144.
44. Obach, R. S. The importance of nonspecific binding in in vitro matrixes, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab. Dispos. 1996, 24(10), 1047-1049.
45. Hall, S. D.; Hamman, M. A.; Rettie, A. E.; Wienkers, L. C.; Trager, W. F.; Vandenbranden, M.; Wrighton, S. A. Relationships between the levels of cytochrome P450 2C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 1994, 22(6), 975-978.